Breaking News on Contract Research, Manufacturing & Clinical Trials

Service Sectors > Phase III-IV

News in brief

Catalent and Cevec team-up to offer protein CDMO services

15-Nov-2012

Catalent and Cevec Pharmaceuticals have joined forces to offer cell line development and manufacturing services to biotechs.

The alliance will combine Catalent’s GPEx gene-insertion tech with Cevec’s CAP cell line protein expression platform, derived from primary human aminocytes.

The deal follows a joint-study for complex protein production, which saw “record” yields of non-antibody proteins produced in a human expression system.

In a joint statement, the firms said they “achieved a manufacturing yield of over three grams per ltr for a secreted, highly glycosylated non-antibody protein, using the challenging hAAT molecule which harbors 3N-glycosylation sites, through a combination of two highly innovative  proprietary technologies.”

Kent Payne, VP and general manager of Catalent’s biologics business said: “We look forward to further drawing on this combination in the development of additional recombinant proteins and antibodies.”

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...